Inclusion Criteria:  Healthy participants according to medical history, physical examination, and baseline safety laboratory tests. All participants must have negative results of a reverse transcriptase polymerase chain reaction test and non-vaccinated participants must have negative results for a serology test within 2 weeks prior to randomization. Able to complete the Follow-up period up to Day 361 as required by the protocol. Body weight ≥ 50 kg to ≤ 110 kg at screening and a Body mass index ≥ 18.0 to ≤ 30 kg/m^2 at the time of the Screening Visit.  Exclusion Criteria:  Known history of allergy or reaction to any component of AZD7442 (AZD8895 + AZD1061). History of infection with SARS or Middle East Respiratory Syndrome. History of laboratory-confirmed SARS-CoV-2 infection or any positive Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) result based on available data at screening. Any clinical signs and symptoms consistent with COVID-19, eg, fever, dry cough, dyspnea, sore throat, fatigue, or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission. History of clinically significant bleeding disorder. Active infection with hepatitis B or C or positive test for hepatitis C or for hepatitis B surface antigen at screening. Immunodeficiency due to illness, including HIV infection, or due to drugs, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone. Any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study Hemoglobin or platelet count below the lower limit of normal at screening. Any prior receipt of another mAb indicated for the prevention or treatment of SARS CoV-2 or COVID-19. Receipt of a mAb within 6 months or 5 antibody half-lives.